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A B S T R A C T   
Friedreich ataxia (FRDA), the most common autosomal recessive ataxia, is characterized by degeneration of 
the large sensory neurons and spinocerebellar tracts, cardiomyopathy, and increased incidence in diabetes. 
The underlying pathophysiological mechanism of FRDA, driven by a significantly decreased expression of 
frataxin (FXN), involves increased oxidative stress, reduced activity of enzymes containing iron‑sulfur clus-
ters (ISC), defective energy production, calcium dyshomeostasis, and impaired mitochondrial biogenesis, 
leading to mitochondrial dysfunction. The peroxisome proliferator-activated receptor gamma (PPARγ) is a 
ligand-activated transcriptional factor playing a key role in mitochondrial function and biogenesis, fatty acid 
storage, energy metabolism, and antioxidant defence. It has been previously shown that the PPARγ/PPARγ 
coactivator 1 alpha (PGC-1α) pathway is dysregulated when there is frataxin deficiency, thus contributing to 
FRDA pathogenesis and supporting the PPARγ pathway as a potential therapeutic target. Here we assess 
whether MIN-102 (INN: leriglitazone), a novel brain penetrant and orally bioavailable PPARγ agonist with an 
improved profile for central nervous system (CNS) diseases, rescues phenotypic features in cellular and an-
imal models of FRDA. In frataxin-deficient dorsal root ganglia (DRG) neurons, leriglitazone increased frataxin 
protein levels, reduced neurite degeneration and α-fodrin cleavage mediated by calpain and caspase 3, and 
increased survival. Leriglitazone also restored mitochondrial membrane potential and partially reversed 
decreased levels of mitochondrial Na+/Ca2+ exchanger (NCLX), resulting in an improvement of mitochon-
drial functions and calcium homeostasis. In frataxin-deficient primary neonatal cardiomyocytes, leriglitazone 
prevented lipid droplet accumulation without increases in frataxin levels. Furthermore, leriglitazone 
improved motor function deficit in YG8sR mice, a FRDA mouse model. In agreement with the role of PPARγ in 
mitochondrial biogenesis, leriglitazone significantly increased markers of mitochondrial biogenesis in FRDA 
patient cells. Overall, these results suggest that targeting the PPARγ pathway by leriglitazone may provide an 
efficacious therapy for FRDA increasing the mitochondrial function and biogenesis that could increase fra-
taxin levels in compromised frataxin-deficient DRG neurons. Alternately, leriglitazone improved the energy 
metabolism by increasing the fatty acid β-oxidation in frataxin-deficient cardiomyocytes without elevation of 
frataxin levels. This could be linked to a lack of significant mitochondrial biogenesis and cardiac hypertrophy. 
Abbreviations: FRDA, Friedreich Ataxia; FXN, frataxin; PPARγ, peroxisome proliferator-activated receptor gamma; PGC-1α, PPARγ coactivator 1 alpha; CNS, 
central nervous system; DRG, dorsal root ganglia; NCLX, mitochondrial Na+/Ca2+ exchanger; ISC, iron‑sulfur clusters; KIKO, knock in-knock out mouse model of 
FRDA; NRVMs, neonatal rat ventricular myocytes; FFA, Free Fatty Acids; CPT-1, carnitine palmitoyltransferase-1; MCAD, medium-chain acyl-CoA dehydrogenase.. 
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The results reinforced the different tissue requirement in FRDA and the pleiotropic effects of leriglitazone 
that could be a promising therapy for FRDA.   
1. Introduction 
Friedreich ataxia (FRDA; OMIM #229300) is an autosomal recessive 
neurodegenerative disease characterized by progressive gait and limb 
ataxia, sensory loss, weakness, dysarthria, and hypertrophic cardiomy-
opathy. It is caused by mutations in the frataxin gene (FXN), most 
commonly expanded GAA triplet repeats in its first intron resulting in 
transcriptional silencing and consequent reduction in the expression of 
the protein frataxin (Campuzano et al., 1996). Frataxin is an ubiqui-
tously expressed mitochondrial protein involved in iron homeostasis, 
biosynthesis of iron‑sulfur clusters (ISC), and energy production in the 
cell (Bencze et al., 2006; Bulteau et al., 2004; Gerber et al., 2003; 
Stehling et al., 2004; Vaubel and Isaya, 2013; Wilson and Roof, 1997). 
Reduction in frataxin expression leads to decreased activity of ISC 
containing enzymes such as aconitase and the mitochondrial respiratory 
chain complexes (Bradley et al., 2000), calcium dyshomeostasis (Abeti 
et al., 2018; Bolinches-Amorós et al., 2014; Mincheva-Tasheva et al., 
2014; Mollá et al., 2019), mitochondrial iron accumulation, oxidative 
stress, and consequently cell death, with the primary affected sites being 
large sensory neurons of the dorsal root ganglia (DRG), the dentate 
nucleus of the cerebellum, and a variety of other central nervous system 
(CNS) cells (Campuzano et al., 1997; Koeppen, 2011; Koeppen et al., 
2009, 2007). However, cardiomyopathy is the most prominent cause of 
death for FRDA patients (Tsou et al., 2011). Currently there is no specific 
therapy to prevent the progression of FRDA (Clay et al., 2019). 
Peroxisome proliferator-activated receptor gamma (PPARγ) is a 
transcription factor that plays essential roles in regulating fundamental 
cellular processes such as differentiation, development and metabolism 
(carbohydrate and lipid); it is also a key regulator of mitochondrial 
function, biogenesis and anti-oxidation effects. PPARγ regulates the 
expression of PPARγ coactivator 1 alpha (PGC-1α), a coactivator of 
PPARγ and a master regulator of mitochondrial biogenesis (Puigserver 
et al., 1998; Puigserver and Spiegelman, 2003). Mitochondrial biogen-
esis deficits occur in the cerebellum of FRDA knock in-knock out mouse 
model (KIKO) (Lin et al., 2017), and decreased PGC-1α levels and 
transcriptional activity have been also observed in multiple cell types 
from FRDA patients and FRDA mouse models (Coppola et al., 2009; 
Marmolino et al., 2010). Concomitantly, decreased mitochondria copy 
number and mitochondrial DNA levels as well as disrupted mitochon-
drial networks have been observed in FRDA cells (Dong et al., 2019; 
Jasoliya et al., 2017), suggesting that abnormalities of mitochondrial 
function and biogenesis deficits can underlie the pathophysiology of 
FRDA. Mitochondrial damage is also observed in frataxin-deficient 
cardiomyocytes affecting the energetic needs of the heart, which 
mainly depend on oxidative catabolism of fatty acids (Obis et al., 2014; 
Purroy et al., 2020). Thus, upregulation of PGC-1α using PPARγ agonists 
may be an appealing therapeutic approach. In this line, it was shown 
that activation of the PGC-1α pathway with PPARγ agonist pioglitazone 
reversed PGC-1α down-regulation in primary fibroblasts from FRDA 
patients suggesting PPARγ agonists as a potential therapeutic approach 
for FRDA (Marmolino et al., 2010). 
Leriglitazone (5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy] 
phenyl]methyl]-1,3-thiazolidine-2,4-dione hydrochloride) is the hy-
drochloride salt of the active metabolite M4 (M-IV) of pioglitazone 
(Actos®, Takeda). Leriglitazone is a novel and orally bioavailable PPARγ 
agonist that engages the target receptor at the levels required for effi-
cacy within the CNS. Compared with other PPARγ agonists, leriglitazone 
shall be used to treat CNS diseases thanks to its adequate brain pene-
tration, good bioavailability, and safety profile (Poli et al., 2020). In the 
present study, we examined the effect of leriglitazone on neurons, car-
diomyocytes, and fibroblasts cell models, and on behavioural 
phenotypes in vivo in the YG8sR mouse model of FRDA. 
2. Materials and methods 
2.1. Human skin fibroblasts culture 
Human skin fibroblasts primary cultures derived from control and 
FRDA patient were obtained from skin biopsy. Fibroblast cell lines F281 
(753/808 GAA repeats), 4654 (333/733 GAA repeats) and 4675 (600/ 
1200 GAA repeats) were obtained from the bank of FRDA patient fi-
broblasts established by Dr. Marek Napierala (The University of Ala-
bama at Birmingham, Birmingham, AL) and Dr. David R. Lynch (The 
Children’s Hospital of Philadelphia, Philadelphia, PA). Fibroblasts were 
cultured in 5% CO2 humidified atmosphere in Dulbecco’s Modified 
Eagle Medium (DMEM): Nutrient Mixture F-12 containing 1% peni-
cillin/streptomycin, 1% non-essential amino acid and 10% fetal bovine 
serum. Cells were treated with leriglitazone at increasing concentrations 
up to 600 nM for two days and then collected in Laemmli sample buffer 
(50 mM Tris-HCl, pH 6.8, 2% SDS, 5 mM EDTA, 0.1% bromophenol 
blue, 10% glycerol, and 2% β-mercaptoethanol) followed by Western 
blot analysis. 
2.2. Isolation and culture of primary rat DRG sensory neurons 
DRGs were extracted from neonatal Sprague–Dawley rats (P3–P4) 
and dissociated with 0.05% trypsin (Sigma-Aldrich, St. Louis, MO). 
Ganglia were mechanically disrupted with a pipette tip until obtaining a 
single cell suspension in culture medium supplemented with DNAse I 
grade II at a final concentration of 3 mg/ml (Roche Diagnostics, Basel, 
Switzerland), which was centrifuged at 800 rpm through 7.5% BSA so-
lution (Sigma-Aldrich, St. Louis, MO) for 5 min, followed by re- 
suspension in enriched neurobasal culture medium consisting of 2% 
horse serum, 2% B27 supplement, 0.5 mM L-glutamine, 100 U/ml peni-
cillin plus 100 ng/ml streptomycin (All from Thermo Fisher Scientific, 
Waltham, MA) and supplemented with murine β-nerve growth factor at 
50 ng/ml (PeproTech, Rocky Hill, NJ). To prevent the growth of non- 
neuronal cells, culture medium was supplemented with the anti- 
mitotic agent Aphidicolin at 3.4 μg/ml (Sigma-Aldrich, St. Louis, MO). 
After 1 h of pre-plating in p60 tissue dish (Corning Inc., Corning, NY) at 
37 ◦C/5%CO2, the cells were then plated in a 24-well tissue dish 
(Corning Inc., Corning, NY) pre-treated with 0.1 mg/ml of collagen 
(Sigma-Aldrich, St. Louis, MO) at a density of 10,000–20,000 cells/well. 
After 1–2 days, lentiviral transduction was performed and 6 h later the 
medium containing lentivirus was replaced by fresh culture medium 
containing leriglitazone at different concentrations (50 nM, 100 nM, 
300 nM, 500 nM) or equal amount of vehicle (DMSO) for five days. The 
culture medium, containing leriglitazone, was changed at 72 h. 
2.3. Isolation and culture of rat ventricular myocytes 
Neonatal rat ventricular myocytes (NRVMs) were obtained as 
described previously (Obis et al., 2014) with some modifications. 
Briefly, ventricles from newborn Sprague–Dawley rats (P3-P4) were 
minced and cells were isolated by 3 subsequent digestions at 37 ◦C with 
150 U/ml of type-2 collagenase (Worthington, Lakewood, NJ). Non- 
cardiomyocyte cells were separated by differential pre-plating. Car-
diomyocytes were seeded on 0.2% gelatin-coated culture dishes at 
7.5–104 cells/cm2 and cultured in medium consisting of DMEM: M199 
(3:1), 5 mM glucose, 8% horse serum, 4% foetal bovine serum, gluta-
MAX and HEPES (all from GIBCO, Waltham, MA). To inhibit the pro-
liferation of cardiac fibroblasts, cells were treated with 10 μg/ml 
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mitomycin C (Sigma-Aldrich, St. Louis, MO) for 4 h after seeding. Car-
diomyocyte purity was checked by immunofluorescence with a specific 
cardiac α-actinin antibody (Sigma-Aldrich, St. Louis, MO). Fatty acid- 
albumin solutions were used for Free Fatty Acids (FFA) supplementa-
tion of the culture medium. A commercial oleic and linoleic-albumin 
solution was used to provide these unsaturated fatty acids. Saturated 
fatty acid-albumin solutions where prepared as described previously 
(Obis et al., 2014; Purroy et al., 2018). These solutions of FFA were 
added to the medium with a final concentration of 30 μM oleic, linoleic 
and stearic acid, and 60 μM of palmitic. Lentiviral transduction was 
performed 4 h after plating and 20 h later the medium containing 
lentivirus was substituted by fresh culture medium containing ler-
iglitazone at different concentrations (0.5 μM, 2 μM) and kept for seven 
days. The culture medium, containing leriglitazone was changed every 
24 h. 
2.4. Lentivirus titration and transduction 
Lentiviral particles were produced as described (Britti et al., 2018; 
Purroy et al., 2018). Briefly, the shRNA lentiviral plasmids (pLKO.1- 
puro) for human/mouse/rat frataxin were purchased from Sigma. The 
RefSeq used was NM-008044, which corresponds to mouse frataxin. The 
Clone used was TRCN0000197534, here referred as FXN1. The vector 
SHC002, a non-targeted scrambled sequence, served as a control (Scr). 
Lentivirus were tittered using the Quicktitter Lentivirus ELISA kit (Cell 
Biolabs, Catalogue #: VPK-108-H) which detects the levels of p24 pro-
tein. For transduction of NRVMs, 5.5 ng p24/1000 cells were added to 
the medium 4 h after plating, and 20 h later, the culture medium was 
replaced with fresh medium. Cells were maintained up to seven days in 
culture (Purroy et al., 2018). For lentiviral transduction of DRG neurons, 
cells were plated in 24-well dishes, and medium containing lentivirus 
particles (20 ng p24/1.000 cell) was added 24 h later. This protocol 
provided transduction efficiency greater than 70%, according to the GFP 
control vector. DRG neurons were used after five days in culture (Britti 
et al., 2018). 
2.5. Immunofluorescence staining 
Five days after lentiviral transduction and leriglitazone treatment, 
frataxin depleted DRG neurons seeded on collagen treated coverslips 
(10,000 cells/per coverslip) were washed twice with PBS and fixed in 
4% paraformaldehyde at room temperature (RT) for 20 min. Cells were 
then washed with PBS, permeabilized with 0.5% TritonX100 at RT for 
30 min and blocked with 1% BSA/ 0.2% Triton X100 in PBS at RT for 
2 h. An antibody to β-III Tubulin (at 1/250 dilution) was then added and 
incubated overnight at 4 ◦C. After washing with PBS, cells were incu-
bated with Alexa Fluor 488 secondary antibody (Invitrogen, Carlsbad, 
CA at 1/250) in the dark for one hour at 37 ◦C followed by nuclei 
staining with DAPI for 5 min. Coverslips were then mounted with 
Mowiol mounting medium (Sigma-Aldrich, St. louis, MO). Immunoflu-
orescent images were taken with an Olympus BX51 microscope with a 
x20 lens and an Olympus U-MNUA2 filter for Dapi and Olympus U- 
MNBA3 filter for β-III Tubulin. 
2.6. Survival and neurite degeneration analysis of DRG neurons 
Neuronal survival was measured with a × 16 lens and cross-marked 
wells. Neurons at zero and 5 days were counted at four fields per cross- 
marked well, using three wells per condition tested. Neurite degenera-
tion was measured with a x20 lens (plus zoom x1.6) and a grid, which 
was created over each image with NIH Image J with the grid plugin 
(Image size 680 × 512 and line area 10,000 pixels). Healthy and 
degenerated neurites (displaying neurofilament aggregates) were 
counted at three grid fields per image and at least three images per well 
were analysed. For each condition, three different wells were used. 
Experiments were repeated at least three times. 
2.7. Assessment of mitochondrial membrane potential (ΔΨm) with JC-1 
The ΔΨm was assessed using the dual-emission, mitochondrion- 
specific, lipophilic, cationic dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetrae-
thylbenzimidazoly-carbocyanine iodide (JC-1) (Abcam, Cambridge, 
MA, Catalogue #: Ab141387) diluted in DMSO, to identify depolarized 
(green) or polarized (red) mitochondria. Cultures of DRG neurons were 
plated in a twenty-four-well tissue dish and analysed for JC-1 at 72 h 
after lentivirus transduction. The cells were first incubated at 37 ◦C 5% 
CO2 with 5 μg/ml JC-1 in neurobasal medium for 30–35 min and then 
washed with PBS at 37 ◦C. Images were taken using an Olympus Fluo-
View IX71 microscope with objective 10×+ 1.6× capable of detecting 
the J-aggregate form of JC-1 using an excitation of 460–500 nm and an 
emission of 510–550 nm (filter Omega XF116-2), the monomeric form of 
JC-1 at an excitation of 520–550 nm and an emission higher than 
510 nm (filter Olympus U-MWIB2), and both forms at an excitation of 
460–490 nm and an emission higher than 510 nm (filter Olympus U- 
MWIG2). Fluorescence is green/yellow in mitochondria with low ΔΨm 
(monomers) and red/orange in those with high ΔΨm (aggregates). 
Pictures were analysed with the Image J software. The region of interest 
(ROI) was the entire image itself using the filter for both forms of JC-1 
and the filter for aggregates, each image was split into three 8-bit 
grayscale images containing the red and green components of the 
original. Once we considered that the split image taken with the filter for 
aggregates also contained the green component, we corrected the fluo-
rescence intensity using this formula: 
Real green fluorescence intensity =Green fluorescence Intensity – 
(Red fluorescence intensity * factor X). 
Factor X = green fluorescence intensity/red fluorescence intensity 
from the image with the filter for aggregates. 
Depolarization is indicated by an increase in the real green/red 
fluorescence intensity ratio. 
2.8. Subcellular lipid labelling and image analysis 
For labelling lipid droplets, cells were washed with PBS and loaded 
with 5 μM BODIPY (493/503) (Invitrogen, Carlsbad, CA) for 20 min at 
37 ◦C. For nuclei staining, Hoechst 33258 (0.05 μg/ml) was used. Cells 
were washed again with PBS and fluorescent images were captured with 
a x20 lens using an Olympus IX71 microscope equipped with epifluor-
escence optics and a DP70 CCD camera. The used values were area of 
lipid droplets per nuclei. 
2.9. Western blot 
Frataxin deficient rat DRG neuron cultures were rinsed three times in 
ice-cold PBS (pH 7.4) and lysed with a buffer containing 2% SDS, 
125 mM Tris and protease inhibitors (Roche) to obtain crude extracts 
used for SDS–polyacrylamide gel electrophoresis (SDS-PAGE). Cultured 
human fibroblasts were collected in Laemmli sample buffer (50 mM Tris- 
HCl, pH 6.8, 2% SDS, 5 mM EDTA, 0.1% bromophenol blue, 10% glyc-
erol, and 2% β-mercaptoethanol). A sample (15–50 μg) of total protein 
was boiled for 5 min and then loaded onto NuPAGE 4–12% Bis-Tris gel 
(fibroblasts) or SDS-polyacrylamide gels (DRGs). Following SDS-PAGE, 
proteins were transferred to nitrocellulose (Sigma-Aldrich, Catalogue 
#: 10600093) or PVDF membranes (Millipore, Catalogue #: 
IPVH00010), blocked with 3% dry milk, and incubated with antibodies 
against: frataxin (Abcam Catalogue #: ab219414), GRP75 (Abcam, 
Cambridge, MA, Catalogue #: ab2799), PGC-1α (Abcam, Cambridge, 
MA, Catalogue #: ab77210), NCLX (LifeSpan BioSciences, Seattle, WA, 
Catalogue #: LS-C102072), α-fodrin (ENZO Life Science, Farmingdale, 
NY, Catalogue #: BML-FG6090-0100), beta tubulin (Cell Signaling, 
Danvers, MA, Catalogue #: 5568) all at dilution 1/1000, frataxin 
(Abcam, Cambridge, MA at 1/500, Catalogue #: ab175402) and β-actin 
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(Chemicon-EMD Millipore, at 1/250000, Catalogue #: MABT825). Blots 
were then incubated with appropriate horseradish peroxidase- 
conjugated secondary antibodies and developed with enhanced chem-
iluminescence (Pierce, Rockford, IL). 
2.10. Animals 
The mouse model of FRDA used in this study was the Fxntm1Mkn Tg 
(FXN)YG8Pook/2 J (YG8sR) (Jackson Laboratory, stock number 
024113) which carries the mouse frataxin knockout allele (Fxn− ) and a 
single copy integration of the human FXN YAC transgene (GAA)250–300. 
As control mice, we used the C57BL/6 J, which shares the genetic 
background of the YG8sR mice. All mice were housed in an environment 
of 12 h light/dark cycle, temperature of 25 ± 2 ◦C, 55% humidity, and ad 
libitum standard diet and water. Studies on C57BL/6 J mice and YG8sR 
were performed in accordance with standard regulations and were 
approved by Bioethics subcommittee of the University of Valencia. 
2.11. Motor performance assessment of YG8sR mice 
We assessed motor function of the YG8sR mouse as the phenotype of 
interest to study the effect of the compound leriglitazone. As control 
mice, we used the C57BL/6 J. The mice were subjected to the rotarod 
test, the pole test, and the balance beam test once a month starting from 
month 3 up to month 11. The mice were initially trained for 4 consec-
utive days before the first trial until each animal performed the different 
tests properly. The treatment with leriglitazone was started for a pro-
portion of the YG8sR mice after the motor tests of month four were 
completed and continued until the sacrifice at eleven months of age. The 
animals were fed ad libitum and the compound was administered as part 
of the food at a concentration of 0.06% (equivalent to 50 mg/kg/day). 
The number of animals in each group were 12 C57BL/6 J, 10 YG8sR and 
11 YG8sR + leriglitazone. 
In the rotarod test, an automated 4-lane accelerating RotaRod (TSE) 
was used to examine motor coordination. This test was performed dur-
ing five consecutive days, and consisted of four trials per day, with in-
tervals of 10 min between each trial. The first day was used only to 
retrain the animals. For each trial, the mice were placed on the rotating 
rod, which accelerates from 4 to 40 rpm over the trial time of 5 min. The 
measure obtained is the time the mouse is able of staying running on top 
the cylinder until it falls (latency time in seconds) and the score 
considered for each month is the average of all the trials. 
The pole test predominantly analyses extrapyramidal motor loco-
motion. This test consisted of 5 consecutive trials, one day per month. 
The mouse was placed head upwards on the top of a pole, whose rough 
surface facilitates the mouse grabbing to the beam. We register the ca-
pacity of turning around and to descend the vertical pole for each mouse. 
A maximum time of 120 s was allowed to execute the task. The measure 
obtained for each month is the percentage of trials the mice were able to 
turn around and descend the pole. 
Sensory-motor coordination was tested using the balance beam test 
with 26 and 12 mm wide bars. Every month, each mouse was given three 
trials per beam. In the test, the mice are placed at the end of the 1 m long 
bars elevated 50 cm above the floor. We measured the time required by 
the mice to cross the bars, and for each month we take as score the 
average of the best two trials for each bar (latency time in seconds). 
2.12. UPLC-MS/MS analysis 
Levels of leriglitazone were quantified in plasma samples from 
YG8sR mice after two weeks of administration by UPLC-MS/MS. Line-
arity was established by a calibration curve with 8 levels different from 
0 prepared by spiking matrix with known concentrations of analytes. A 
known concentration of internal standard was added in each sample. 
Acceptance criteria: the deviation of standards used to perform the 
calibration curve should be ≤15% from nominal concentration, except 
in the LOQ, which can be 20%. 
2.13. Statistical analysis 
GraphPad. PRISM® software (GraphPad Software Inc.) was used to 
generate the graphs and to perform statistical analysis. The results are 
expressed as mean ± SEM. Statistical test performed was stated in the 
corresponding figure legend. Significant p-values: *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001 were considered. 
3. Results 
3.1. Leriglitazone increases frataxin amounts in frataxin-deficient DRG 
neurons 
To investigate whether leriglitazone has a positive impact on 
frataxin levels, we first treated frataxin-deficient rat primary DRG 
neuron cultures. For this purpose, DRG neurons were transduced 
with lentivirus carrying FXN shRNA (FXN1) to reduce the endoge-
nous expression level of frataxin, or scrambled shRNA (Scr) as con-
trol condition for frataxin endogenous levels. Crude extracts 
obtained after five days of leriglitazone treatment were analysed by 
western blotting and the results are shown in Fig. 1. As previously 
reported (Britti et al., 2018), lentivirus transduction with FXN1 
decreased frataxin levels in DRG neurons by 58% compared with 
lentivirus containing Scr (Fig. 1) (58% decrease from Scr vehicle, 
p < 0.0001, n = 8). Treatment of frataxin-deficient DRG neurons with 
leriglitazone at 500 nM exerted a significant 48% increase of frataxin 
Fig. 1. Leriglitazone increases frataxin levels in frataxin-deficient DRG neu-
rons. (A) Crude extracts of primary cultures of frataxin-deficient DRG neurons 
(FXN1) and controls (Scr), obtained as described in materials and methods, 
were tested for frataxin amounts after leriglitazone treatment at 500 nM by 
Western blot. Actin was used as a loading control. (B) Quantitative analysis of 
frataxin levels expressed as % of control (Scr vehicle). Data is expressed as 
mean ± SEM from 8 independent experiments and was analysed by Student’s t- 
test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 
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compared to vehicle treated cells (Fig. 1). 
3.2. Leriglitazone rescues cell survival, neurite degeneration and 
mitochondrial function in frataxin-deficient DRG neurons 
Frataxin depletion in DRG neurons promotes neurite degeneration 
indicated by the formation of neurofilament aggregates and leads to 
depolarization of mitochondria, calcium dysregulation and apoptotic 
cell death (Mincheva-Tasheva et al., 2014). Thus, we examined whether 
leriglitazone rescues the neuronal phenotype and cell viability in 
frataxin-deficient DRG neurons. Briefly, DRG neurons were transduced 
with lentivirus carrying FXN1 or Scr and treated with leriglitazone for 
5 days followed by survival, neurite degeneration, mitochondrial 
membrane potential, and western blot analysis, as detailed in material 
and methods. Consistent with previous reports (Britti et al., 2018; 
Mincheva-Tasheva et al., 2014), transduction with lentivirus carrying 
FXN1 decreased the number of surviving DRG neurons (Fig. 2A) (48% 
decrease compared to Scr vehicle, p < 0.0001, n = 4). Treatment with 
leriglitazone increased survival of frataxin-deficient DRG neurons in a 
dose-dependent manner, with maximal effect at 500 nM (Fig. 2A) (44% 
increase over FXN1 vehicle, p < 0.0001, n = 4). Frataxin depletion also 
promoted neurite degeneration in DRG neurons as evidenced by 
swelling and increased neurofilament aggregates (Fig. 2B and C) (92% 
increase from Scr vehicle, p < 0.0001, n = 3). The treatment with ler-
iglitazone at 500 nM decreased the number of neurofilament aggregates 
(Fig. 2B and C) (44% decrease from FXN1 vehicle, p < 0.0001, n = 3) 
and restored the morphology of neurites. These results indicate that 
leriglitazone ameliorates neurite degeneration and promotes cell sur-
vival in frataxin-deficient DRG neurons. 
We next examined whether leriglitazone blocks the apoptotic 
events leading to α-fodrin cleavage and decreased mitochondrial 
membrane potential. An intracellular increase of calcium activates 
calcium-dependent proteases leading to the cleavage of the cyto-
skeletal protein, α-fodrin. Transduction of DRG neurons with lenti-
virus carrying FXN1 led to α-fodrin cleavage, into a non-specific 
150 kDa fragment and a calpain-specific 145 kDa fragment or a cas-
pase 3-specific 120 kDa product (Fig. 3A and B), as previously 
described (Purroy et al., 2018). Leriglitazone treatment (500 nM) 
decreased the levels of 150/145 kDa and 120 kDa fragments (Fig. 3A 
and B) (150/145 kDa, p < 0.05; 120 kDa, p < 0.001, n = 8). Similarly, 
DRG neurons lentiviral transduction with FXN1 increased the ratio of 
green/red fluorescence of JC-1 (Fig. 3C and D), indicating a 
decreased mitochondrial membrane potential and compromised 
mitochondrial function. In contrast, leriglitazone treatment restored 
the membrane potential close to control Scr vehicle values (Fig. 3C 
and D) (p < 0.01, n = 3). Finally, we examined whether leriglitazone 
affects mitochondrial Na+/Ca2+ exchanger (NCLX) levels. NCLX is 
associated with frataxin deficiency in frataxin-deficient DRG neu-
rons, frataxin-deficient cardiomyocytes, and lymphoblastoid cell 
lines from patients (Purroy et al., 2018). NCLX levels have been 
previously shown to decrease in frataxin deficiency which are 
restored either by using frataxin replacement or by the calcium 
Fig. 2. Leriglitazone rescues cell survival and neurite degeneration in frataxin-deficient DRG neurons. Rat primary DRG neurons were transduced with lentivirus 
carrying FXN1 or Scr and treated with leriglitazone for 5 days followed by survival and neurodegeneration analysis. (A) Percentage of survival of frataxin-deficient 
DRG neurons in the presence of increasing concentrations of leriglitazone up to 500 nM compared to Scr vehicle. (B) Representative β-III-Tubulin immunofluo-
rescence microscopy images of 5-day cultures treated with leriglitazone (500 nM) or vehicle solution. Arrows show neurite aggregates present only in degenerated 
neurons. Scale bar 30 μm. (C) Quantification of neurites aggregates versus total neurites of DRG neurons after treatment with leriglitazone (500 nM). All data is 
expressed as mean ± SEM and was statistically analysed by one-way ANOVA. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 
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chelator BAPTA (Purroy et al., 2018). In addition, calpains inhibition 
improves the NCLX levels (Britti et al., 2020). Transduction of DRG 
neurons with lentivirus carrying FXN1 significantly decreased the 
levels of NCLX in frataxin-deficient DRG neurons (Fig. 3E and F) 
(60% decrease from control, p < 0.0001, n = 7). Treatment with ler-
iglitazone (500 nM) partially restored levels of NCLX (Fig. 3E and F) 
(69.8% increase compared to FXN1 vehicle, p < 0.05, n = 7). Taken 
together, these results would indicate that leriglitazone acts at 
multiple levels to slow down DRG neurons degeneration caused by 
frataxin deficiency, by improving mitochondrial function and cal-
cium homeostasis. 
3.3. Leriglitazone reduces lipid droplet formation in frataxin-deficient 
cardiomyocytes without changing frataxin levels 
We next investigated whether leriglitazone modifies frataxin protein 
levels and reduces lipid droplet formation, a marker of lipid metabolism 
dysfunction, in frataxin-deficient cardiomyocytes. Neonatal rat 
Fig. 3. Leriglitazone improves mitochondrial function in frataxin-deficient DRG neurons. Rat primary DRG neurons were transduced with lentivirus carrying FXN1 
or Scr and treated with leriglitazone at 500 nM for 5 days followed by western blot or immunofluorescence analysis. (A) Representative western blot and (B) 
quantification of relative amounts of fragmented α-fodrin (145/150 KDa and 120 KDa) in the absence or presence of leriglitazone (500 nM) compared to Scr vehicle. 
(C) Representative microscopy images of DRG neurons transduced with FXN1 or Scr in the absence or presence of leriglitazone (500 nM) followed by JC-1 assay. 
Scale bar 30 μm. (D) Ratio green/red JC-1 assay expressed as % of Scr vehicle in the absence or presence of leriglitazone (500 nM). (E) Representative western blot 
and (F) quantification of relative amounts of NCLX in the absence or presence of leriglitazone (500 nM) compared to Scr vehicle. All the results are shown as 
mean ± SEM, and t-test and one-way ANOVA were used for the statistical analysis (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this article.) 
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ventricular myocytes (NRVMs) were cultured and transduced with 
lentivirus carrying FXN1 sequence or Scr and treated with leriglitazone 
at two different concentrations (0.5 μM and 2 μM) for 7 days followed by 
western blotting to detect frataxin protein or BODIPY (493/503) stain-
ing to visualize lipid droplets. Transduction of NRVMs with lentivirus 
containing FXN1 led to 24% residual frataxin compared with Scr, similar 
to previously reported (Obis et al., 2014). Treatment with leriglitazone 
at 0.5 and 2 μM for 7 days did not change frataxin protein levels in 
frataxin-deficient cardiomyocytes (Fig. 4A and B). Thus, the effect of 
leriglitazone on frataxin levels was cell-type dependent since frataxin 
levels were increased in frataxin-deficient DRG neurons after ler-
iglitazone treatment but no changes were observed in frataxin-deficient 
cardiomyocytes. Lipid droplets accumulated in frataxin deficient car-
diomyocytes but not in those transduced with Scr control (Fig. 4C and 
D). Leriglitazone treatment (2 μM) efficiently reduced lipid droplet 
appearance (Fig. 4C and D) (42.3% decrease from FXN1 vehicle, 
p < 0.001, n = 5). No significant effect was observed at a lower con-
centration of leriglitazone (0.5 μM). These results indicate that ler-
iglitazone prevents lipid accumulation in frataxin-deficient 
cardiomyocytes. 
3.4. Leriglitazone improves motor performance in YG8sR mice 
The YG8sR mouse used in the study is a FXN YAC transgenic mouse 
that is homozygous for a knockdown of the mouse frataxin gene (Fxn− ) 
and hemizygous for the YG8s transgene, which contains in a single 
integration site a single copy of the human FXN gene with a tract of 
~200 GAA trinucleotide repeats. These mice are rescued from the em-
bryonic lethality caused by the Fxn knockout and show a degree of 
glucose intolerance and insulin hypersensitivity, as well as pathological 
alterations in the neurons of the dorsal root ganglia (Muñoz-Lasso et al., 
2020) and a mild and progressive motor deficit phenotype that re-
sembles a FRDA-like pathology (Anjomani Virmouni et al., 2015). 
We next examined whether leriglitazone rescues motor deficits in the 
YG8sR mice that show progressive motor dysfunction over time. C57BL/ 
6 J mice containing the genetic background in which the YG8sR was 
developed were used as control. Leriglitazone was administered into the 
food at a concentration of 0.06% (equivalent to 50 mg/kg/day). Plasma 
levels of leriglitazone were quantified by UPLC-MS/MS after two weeks 
of administration to confirm that the drug had reached the expected 
levels, 15.2 ± 0.5 μg/ml, that would correspond to a concentration of 
50 mg/kg/day in plasma from YG8sR mice after treatment. To deter-
mine the efficiency of leriglitazone in an animal model, a pre-clinical 
trial was programmed with three groups of mice: C57BL/6 J (n = 12), 
YG8sR (n = 10), YG8sR + leriglitazone 0.06% (equivalent to 50 mg/kg/ 
day) (n = 11). Motor function was tested monthly in all mice with the 
rotarod, pole test and balance beam tests using the 12 and 26 mm wide 
beams, starting from the third month and until the time of sacrifice at 
month 11. Treatment with leriglitazone started from the 4th month after 
randomization of the YG8sR mice into two groups: YG8sR (control 
Fig. 4. Leriglitazone reduces lipid droplet accumulation in frataxin-deficient cardiomyocytes. NRVMs were transduced with lentivirus carrying frataxin shRNA 
(FXN1) or Scr sequence for 7 days followed by western blot for frataxin or BODIPY 493/503 staining to visualize lipid droplets. (A) Representative western blot and 
(B) quantification of relative amounts of frataxin in the absence and presence of leriglitazone (0.5 and 2 μM) compared to Scr vehicle. Coomassie brilliant blue (CBB) 
was used as a loading control. (C) Representative images of 7-day cultures treated with leriglitazone (2 μM) showing diminished lipid droplets compared with Scr 
vehicle control. DAPI was used for nuclei staining. Scale bar 30 μm. (D) Percentage of lipid droplets per cell after leriglitazone treatment (up to 2 μM) compared to 
FXN1 vehicle. Data is expressed as mean ± SEM and was statistically analysed by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). (For 
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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untreated) and the YG8sR + leriglitazone. The monitoring lasted until 
the sacrifice at 11 months of age. Mouse body weights were recorded 
once a month from 3 to 11 months of age. The data obtained revealed an 
earlier gain of body weight in the YG8sR mice compared with C57BL/ 
6 J, that was not reduced after treatment with leriglitazone (Supple-
mental Fig. S1). The execution of behavioural tests (Balance beam and 
rotarod) by the groups started to be differentiated at the 3rd month of 
age of the animals. For each test and group of mice, it is shown the 
performance change between the beginning of the study (average per-
formance of months 3 and 4) and the end of the study (average per-
formance of months 9 to 11) (Fig. 5A-D). It is also shown the progression 
of the performance for each month along the study (Fig. 5E-H). 
On the rotarod test, YG8sR mice performed worse than the C57BL/ 
6 J, being the differences statistically significant for months 3, 4 and 11 
Fig. 5. Leriglitazone improves motor performance in YG8sR mouse model. (A-D) Percentage of change in performance between the beginning (average score of 
months 3 and 4) and the end of the study (average score of months 9 to 11) for rotarod (A), pole test (B) and balance beam test using the 26 (C) and 12 mm (D) wide 
bars. (E-H) Progression of the motor performance for all the months along the study for rotarod (E), pole test (F) and balance beam test using the 26 (G) and 12 mm 
(H) wide bars. The treatment with leriglitazone improve the performance of the YG8sR mice in the case of the balance beam test with the 26 mm bar (G) and 
12 mm bar (H). (I) Global motor performance of the different groups calculated as the average of the performance changes in the different tests. YG8sR mice generally 
perform worse than the control C57BL/6 J mice can be corrected in a great extent with the treatment with leriglitazone. (J) Radial representation of the performance 
change of the different tests highlights that the greater differences between the groups are detected with the balance beam test. For A-D and I results are expressed as 
mean ± SEM and differences between groups were determined using one-way analysis of variance (ANOVA), followed by a Dunnett post hoc test. For E-H differences 
between groups were determined using Mixed-effects analysis, followed by a Dunnett post hoc test. Significant p-values: *p < 0.05; **p < 0.01. 
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(Fig. 5E). However, there were no differences between WT and YG8sR in 
the performance change percentage between beginning and end of the 
study due to their very similar rate of performance loss (Fig. 5A). The 
treatment with leriglitazone did not have a statistically significant effect 
on the performance of the YG8sR mice (Fig. 5A and E), despite a slight 
improvement in the performance change percentage (Fig. 5A). 
In the pole test, the YG8sR mice performed worse than the C57BL/ 
6 J, at least until month 10 (statistically significant difference for month 
9), at which point the control mice also experimented a clear decay in 
their performance (Fig. 5F). In this test, the treatment did not improve 
the performance of the YG8sR mice either (Fig. 5B and F). 
Nevertheless, in the case of the balance beam test, the treatment with 
leriglitazone clearly improved the performance of the YG8sR mice, both 
with the 26 and 12 mm wide bars. The performance of the YG8sR mice 
was statistically worse than C57BL/6 J for months 5, 9 and 10 in the 
26 mm bar (Fig. 5G) and for months 9 and 10 in the 12 mm bar (Fig. 5H). 
The treatment improved the performance of the YG8sR mice, being the 
differences statistically significant for months 9 and 10 in the 26 mm bar 
(Fig. 5G) and for month 9 in the 12 mm bar (Fig. 5H). The differences in 
performance change between the beginning and the end of the study 
were also noticeable and statistically significant between the different 
groups (Fig. 5C-D). 
Fig. 6. Leriglitazone increases PGC-1α, GRP75 and frataxin levels in both control and FRDA patient derived-skin fibroblasts. Skin fibroblasts derived from control 
and FRDA patient (F281) were treated with leriglitazone for 48 h and then lysed and subjected to Western blot analysis using antibodies to PGC-1α, GRP75 and 
frataxin. The amount of immunoreactivity in the lysates was quantified as a percentage of vehicle. Representative blots and bar graphs demonstrate increased levels 
of PGC-1α and GRP75 in both control fibroblasts (A) and F281 FRDA patient fibroblasts (B) following leriglitazone treatment. Leriglitazone also increases frataxin 
levels in control (C) and FRDA patient-derived fibroblasts (D). Data is shown as mean ± SEM (error bars) and was analysed by Student’s t-test (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
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The YG8sR mice experienced a clear worsening in their performance 
in comparison with the C57BL/6 J, while the treatment with ler-
iglitazone reversed this situation. Then, we calculated an overall global 
motor performance by taking the mean of the performance change 
percentages obtained in the rotarod, pole test and balance beam. 
Compared with the C57BL/6 J mice, the YG8sR demonstrated a signif-
icant impaired motor performance, and leriglitazone treatment rescued 
the motor function deficit of the YG8sR mice (Fig. 5I and J). 
3.5. Leriglitazone increases PGC-1α, GRP75 and frataxin levels in human 
skin fibroblasts from control and FRDA patients 
To understand the mechanism underlying the protective effect of 
leriglitazone on DRG neuronal survival, lipid metabolism and motor 
function in FRDA models, and also to investigate whether leriglitazone 
exhibits effect on FRDA patient cells, we examined the levels of PGC-1α 
in FRDA fibroblasts treated with increasing concentrations of ler-
iglitazone for two days. Leriglitazone significantly increased PGC-1α 
levels in both control (Fig. 6A) and FRDA F281 patient fibroblasts (750/ 
808 GAA repeats), (Fig. 6B). Similarly, leriglitazone significantly 
increased the levels of GRP75, a nuclear encoded mitochondrial chap-
erone downregulated in FRDA (Dong et al., 2019), in both control 
(Fig. 6A) and FRDA F281 patient-derived fibroblasts (Fig. 6B). These 
results suggest that leriglitazone promotes mitochondrial biogenesis in 
both control and FRDA F281 patient-derived fibroblasts. In addition, 
leriglitazone dose dependently increased frataxin levels in both control 
(Fig. 6C) and FRDA F281 patient-derived fibroblasts (Fig. 6D) with 
maximal effects observed at 600 nM for both control (623% increase 
over vehicle, 5 independent experiments, p = 0.0575) and patient fi-
broblasts (472% increase over vehicle, 4 independent experiments, 
p < 0.05). Analysis on additional FRDA patient-derived fibroblast cell 
lines were in the same direction (Supplemental Fig. S2). These results 
indicate that leriglitazone increases frataxin levels in both control and 
FRDA patient-derived skin fibroblasts. 
4. Discussion 
In the present study we have demonstrated that across several 
models leriglitazone rescues cellular, biochemical and behavioural fea-
tures of frataxin deficiency. This includes morphological and biochem-
ical features in cultured neurons, metabolic deficits on cardiomyocytes 
cultures, behavioural components in YG8sR mouse model, and 
biochemical aspects of cells from FRDA patients. This reversion towards 
a normalized phenotype is due to an improvement in the mitochondrial 
function and biogenesis with an increase in frataxin levels in primary 
DRG neurons and in patients’ fibroblasts. In contrast, the optimization of 
lipid metabolism in frataxin-deficient cardiomyocytes is not associated 
with an increase in frataxin levels. Given the widely varying features of 
these models, these results confirm that leriglitazone represents a po-
tential therapeutic agent. 
Previous findings show that PPARγ activation by Azelaoyl-PAF in-
creases frataxin levels in human fibroblasts (Marmolino et al., 2009). In 
our study with FRDA fibroblasts and in frataxin-deficient DRG neurons 
we observed that leriglitazone efficiently induces the expression of fra-
taxin. Moreover, leriglitazone also induces the expression of PGC-1α and 
its downstream target GRP75 in both control and FRDA patient-derived 
fibroblasts, suggesting that the activation of PPARγ can stimulate 
mitochondrial biogenesis in these cells. While PGC-1α induction could 
increase both nuclear and mitochondrial genome encoded proteins 
through increased transcription, increased GRP75 could further increase 
the levels of these proteins through its chaperone activity, which sta-
bilizes the frataxin precursor and increases its import and processing 
(Dong et al., 2019). 
DRG neurons undergo apoptosis upon induction of frataxin defi-
ciency. Leriglitazone reverses many of the apoptotic events downstream 
from frataxin deficiency, including fodrin cleavage and mitochondrial 
depolarization. While these serve as markers of apoptosis, they also in 
themselves play roles in the pathophysiological process. In addition, 
reduction of the mitochondrial calcium exchanger NCLX impairs mito-
chondrial calcium efflux (Purroy et al., 2018). Calcium overload can also 
activate mitochondrial calpains leading to further decreases of NCLX 
levels, by the fact that calpain inhibitors can increase its levels, thus 
forming a toxic positive feedback (Britti et al., 2020). Leriglitazone not 
only restores the levels of NCLX but also blocks calpain and caspase 3 
mediated α-fodrin cleavage and recovers mitochondrial membrane po-
tential. All these effects contribute to the protective effect of ler-
iglitazone on DRG neurons probably by preventing the mitochondrial 
(intrinsic) pathway of apoptosis. On the other hand, leriglitazone could 
promote DRG neuronal survival through increased expression of anti- 
apoptotic molecules. PPARγ activation by agonists such as pioglita-
zone and rosiglitazone increases B-cell lymphoma 2 (Bcl-2) and B-cell 
lymphoma-extra large (Bcl-xL) expression and ameliorates neuronal loss 
in a number of cellular and animal models of neurodegenerative diseases 
(Fuenzalida et al., 2007; Jung et al., 2006; Qin et al., 2015; Wu et al., 
2009). Thus, the expression of these anti-apoptotic proteins could pro-
tect neurons against apoptotic stimuli. 
Another mechanism of action by PPARγ to take into account is the 
regulation of antioxidant response via PGC-1α and Nrf2. Oxidative stress 
is a pathogenic contributor in FRDA models (Bulteau et al., 2012; Pas-
tore et al., 2003; Purroy et al., 2020). PGC-1α silencing by siRNA in 
normal fibroblasts mimics the lack of antioxidant response found in 
FRDA cells and stimulating PPARγ or AMPK restores the antioxidant 
SOD2 response in H2O2 stressed FRDA cells (Marmolino et al., 2010). In 
addition, Nrf2 expression and transcripts encoding the antioxidants, 
which are controlled by PGC-1α (Gureev et al., 2019), were decreased in 
DRG tissue in a mouse model of FRDA (Shan et al., 2013). Thus, through 
activation of PPARγ, leriglitazone could act at multiple levels to stim-
ulate antioxidant response to protect DRG neurons and promote 
neuronal survival. 
The effect of leriglitazone on frataxin-deficient cardiomyocytes em-
phasizes the metabolic aspects of FRDA. Lipid accumulation, as 
demonstrated by the formation of lipid droplets, appears in vitro in 
frataxin-deficient primary cultured cardiomyocytes (Obis et al., 2014), 
in vivo in the cardiac muscle of FRDA cardiac knockout mouse (Puccio 
et al., 2001), and in glia in a drosophila model of FRDA (Navarro et al., 
2010). Lipid accumulation can be attributed to either increased syn-
thesis or defective catabolism including fatty acid β-oxidation. Respi-
ratory chain protein deficiency or pharmacologically inhibiting 
respiratory chain function leads to lipid accumulation (Vankoningsloo 
et al., 2005; Watmough et al., 1990), suggesting that mitochondrial 
dysfunction can be a direct cause of lipid accumulation. These alter-
ations caused by mitochondrial impairment can have important conse-
quences in heart cells since they need high amount of energy and mainly 
depend on oxidative catabolism of fatty acids for such energy. PPARγ 
plays critical roles in fatty acid β-oxidation through controlling the 
expression of its target genes. Decreasing PPARγ transcriptional activity 
downregulates carnitine palmitoyltransferase-1 (CPT-1), which cataly-
ses the rate-limiting step of fatty acid β-oxidation, and medium-chain 
acyl-CoA dehydrogenase (MCAD) leading to lipid accumulation 
(Gulick et al., 1994; Vankoningsloo et al., 2005). Thus, the preventive 
effect of leriglitazone on lipid droplet formation in frataxin-deficient 
cardiomyocytes might reflect increased CPT-1 and MCAD expression 
by PPARγ. The protective role by PPARγ in cardiomyocytes has been 
recently supported by a study with PPARγ KO mice. PPARγ may prevent 
myocardial ischemia-reperfusion injury by modulating the Nuclear 
factor-κB (NF-kB)-associated inflammatory mechanisms (Lee and Kim, 
2015). In addition, PPARγ gene expression is decreased in primary 
frataxin-deficient cardiomyocytes without changes in PGC-1α levels and 
with increased presence of lipid droplets compared to wild-type car-
diomyocytes (Obis et al., 2014). As we show with our results, restoring 
PPARγ levels could alter the regulation of fatty acid β-oxidation to 
improve the energetic status of these cells. 
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The levels of the PGC-1α in the heart of FRDA patients are still 
controversial because a tendency of PGC-1α upregulation has been 
observed in a deficient frataxin cardiac cell line, which could potentially 
contribute to an undesired hypertrophic effect (Coppola et al., 2009). 
Our results showed unchanged frataxin levels in cardiomyocytes after 
leriglitazone treatment in contrast to the increase observed in frataxin- 
deficient DRG, which would indicate that mitochondrial biogenesis 
that could lead to a cardiac hypertrophy may not be relevant in this cell 
type. These results may reflect differential expression and regulation in 
different tissues as already suggested (Lin et al., 2017). Altogether, these 
data suggest that the effect of leriglitazone preventing lipid accumula-
tion through PPARγ may be mediated preferentially by regulation of 
fatty acid β-oxidation and in less amount to an improvement of mito-
chondrial functionality. 
To investigate the effect of oral leriglitazone administration on 
locomotor behaviour in YG8sR mouse model we used four behavioural 
tests that are employed to analyse cerebellar function in mice. After 
seven months of chronic treatment, results show that leriglitazone 
partly improves motor function. The performance in the rotarod and 
pole tests was very similar between the group of YG8sR and 
YG8sR + leriglitazone mice, but nevertheless an improvement was 
observed in the balance beam test. A global analysis of the perfor-
mance of the mice showed that the YG8sR mice experiment up to 50% 
more decline than the control that recovered after treatment with 
leriglitazone. 
In summary, leriglitazone protects the DRG neurons from 
apoptotic cell death, and improves motor function deficit in FRDA 
mouse model. These effects could be mediated in part by increased 
mitochondrial biogenesis and functionality that lead to an increase in 
frataxin levels. In addition, leriglitazone can reduce lipid accumu-
lation in frataxin-deficient cardiomyocytes by improving the fatty 
acid β-oxidation compromised in FRDA without elevation of frataxin 
levels and probably linked to a lack of significant mitochondrial 
biogenesis and cardiac hypertrophy. The results reinforced the 
different tissue requirement in FRDA and the pleiotropic effects of 
leriglitazone that could cover the multiple features of the disease. 
Since leriglitazone can be administered orally with high brain 
penetration efficiency (Poli et al., 2020), our results support a further 
study of this compound in clinical settings of FRDA. Leriglitazone is 
currently being evaluated in a phase II clinical trial in patients with 
FRDA. 
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Obis, È., Irazusta, V., Sanchís, D., Ros, J., Tamarit, J., 2014. Frataxin deficiency in 
neonatal rat ventricular myocytes targets mitochondria and lipid metabolism. Free 
Radical Biol. Med. 73, 21–33. https://doi.org/10.1016/j. 
freeradbiomed.2014.04.016. 
Pastore, A., Tozzi, G., Gaeta, L.M., Bertini, E., Serafini, V., Cesare, S.D., Bonetto, V., 
Casoni, F., Carrozzo, R., Federici, G., Piemonte, F., 2003. Actin Glutathionylation 
Increases in Fibroblasts of Patients with Friedreich’s Ataxia: a potential role in the 
pathogenesis of the disease. J. Biol. Chem. 278, 42588–42595. https://doi.org/ 
10.1074/jbc.M301872200. 
Poli, S., Vilalta, A., Rodríguez-Pascau, L., Cerrada-Gimenez, M., Berger, J., Forss- 
Petter, S., Weinhofer, I., Musolino, P., Martinell, M., Pizcueta, P., 2020. MIN-102 
(leriglitazone), a Brain Penetrant PPAR gamma Agonist, Decreases 
Neuroinflammation and Neurodegeneration and Promotes Re-Myelination in 
Preclinical Models of X-linked Adrenoleukodystrophy (X-ALD) (759). Neurology 94. 
Puccio, H., Simon, D., Cossée, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., 
Matyas, R., Rustin, P., Koenig, M., 2001. Mouse models for Friedreich ataxia exhibit 
cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by 
intramitochondrial iron deposits. Nat. Genet. 27, 181–186. https://doi.org/ 
10.1038/84818. 
Puigserver, P., Spiegelman, B.M., 2003. Peroxisome proliferator-activated receptor- 
gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic 
regulator. Endocr. Rev. 24, 78–90. https://doi.org/10.1210/er.2002-0012. 
Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M., Spiegelman, B.M., 1998. 
A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. 
Cell 92, 829–839. https://doi.org/10.1016/s0092-8674(00)81410-5. 
Purroy, R., Britti, E., Delaspre, F., Tamarit, J., Ros, J., 2018. Mitochondrial pore opening 
and loss of Ca2+ exchanger NCLX levels occur after frataxin depletion. Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease 1864, 618–631. https://doi.org/ 
10.1016/j.bbadis.2017.12.005. 
Purroy, R., Medina-Carbonero, M., Ros, J., Tamarit, J., 2020. Frataxin-deficient 
cardiomyocytes present an altered thiol-redox state which targets actin and pyruvate 
dehydrogenase. Redox Biol 32, 101520. https://doi.org/10.1016/j. 
redox.2020.101520. 
Qin, H., Tan, W., Zhang, Z., Bao, L., Shen, H., Wang, F., Xu, F., Wang, Z., 2015. 15d- 
prostaglandin J2 protects cortical neurons against oxygen-glucose deprivation/ 
reoxygenation injury: involvement of inhibiting autophagy through upregulation of 
Bcl-2. Cell. Mol. Neurobiol. 35, 303–312. https://doi.org/10.1007/s10571-014- 
0125-y. 
Shan, Y., Schoenfeld, R.A., Hayashi, G., Napoli, E., Akiyama, T., Iodi Carstens, M., 
Carstens, E.E., Pook, M.A., Cortopassi, G.A., 2013. Frataxin deficiency leads to 
defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the 
Friedreich’s ataxia YG8R mouse model. Antioxid. Redox Signal. 19, 1481–1493. 
https://doi.org/10.1089/ars.2012.4537. 
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